Sonoma Pharmaceuticals
SNOA
14 hedge funds and large institutions have $1.13M invested in Sonoma Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 13 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
40% less capital invested
Capital invested by funds: $1.89M → $1.13M (-$757K)
44% less funds holding
Funds holding: 25 → 14 (-11)
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.9K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$4.31K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$2.58K |
| 4 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
+$861 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$861 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$348K |
| 2 |
Goldman Sachs
New York
|
-$63K |
| 3 |
GW
GW & Wade
Wellesley,
Massachusetts
|
-$43K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$31K |
| 5 |
NL
NWAM LLC
Mercer Island,
Washington
|
-$23K |
SNOA Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2016, worth a combined $1.13M — down 40% from $1.89M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SNOA and 2 opened new positions — a net loss of 11 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $31.9K. The largest seller was Anson Funds Management, exiting entirely with an estimated $348K sold.
- 14 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2016, down from 25 in Q1 2016.
- Funds reported $1.13M of Sonoma Pharmaceuticals stock for Q2 2016, down 40% quarter-over-quarter.
- 2 funds opened new Sonoma Pharmaceuticals positions in Q2 2016 and 13 closed out, a net change of -11 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2016 was Vanguard Group, an estimated $31.9K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2016 was Anson Funds Management, an estimated $348K sold.
Based on aggregated 13F filings for Q2 2016.